James Wolfe, MD
Allergy & Immunology · San Jose, CANPI 1194733428
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,237 of the $178,361 with a category attached, or 95.4%. Cipla USA Inc. accounts for 95.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $171,226 and has fallen 99.0% since, to $1,752 in 2025. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $439.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$170K
- AstraZeneca$3K
- GSK$2K
- Novartis$449
- Regeneron Healthcare Solutions, Inc.$349
- Sanofi$341
- plus $2K from 23 others
Across 184 payments — averaging $12,853 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$931K
- Teva Pharmaceuticals USA, Inc.$496K
- Amphastar Pharmaceuticals, Inc.$355K
- Chiesi USA, Inc.$192K
- Astrazeneca UK Limited$160K
- Sanofi US Services Inc.$87K
- plus $145K from 4 others
What the payments were for
- Speaking & faculty fees$170,23795%
- Travel & lodging$2390%
- Food & beverage$7,8554%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 7 | $170,237 |
| AstraZeneca | 132 | $3,248 |
| GSK | 126 | $1,982 |
| Novartis | 23 | $449 |
| Regeneron Healthcare Solutions, Inc. | 14 | $349 |
| Sanofi | 10 | $341 |
| ARS Pharmaceuticals Operations, Inc. | 17 | $212 |
| Alk-abello, Inc | 17 | $206 |
| Teva Pharmaceuticals USA, Inc. | 6 | $158 |
| Optinose US, Inc. | 7 | $155 |
| Boehringer Ingelheim | 7 | $141 |
| Mylan Specialty L.p. | 6 | $114 |
| Pfizer | 4 | $85 |
| Shire North American Group Inc | 4 | $84 |
| CSL Behring | 3 | $79 |
| Covis Pharma GmbH | 3 | $73 |
| Hikma Pharmaceuticals USA | 4 | $72 |
| Merck | 2 | $66 |
| Kaleo, Inc. | 3 | $60 |
| Philips North America LLC | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 1 | $29 |
| Grifols USA, LLC | 1 | $28 |
| LEO Pharma Inc. | 1 | $26 |
| Advanced Respiratory, Inc | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$178,361 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 104 | $402,004 |
| Dupixent PenDupilumab | 95 | $379,061 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 150 | $141,233 |
| AlvescoCiclesonide | 103 | $110,979 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $81,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $29,470 |
| Arnuity ElliptaFluticasone Furoate | 39 | $17,144 |
| Azelastine Hcl | 312 | $14,917 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,680 |
| Ipratropium Bromide | 254 | $11,501 |
| Hydroxyzine Hcl | 293 | $10,509 |
| Fluticasone Propionate HfaFluticasone Propionate | 15 | $7,949 |
| Clarithromycin | 135 | $7,453 |
| Fluticasone Propionate | 42 | $6,248 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $5,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKAnoro Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,982 | $187,847210 claims |
| Covis Pharma GmbHAlvesco | $73 | $110,979103 claims |
| AstraZenecaBevespi Aerosphere | $3,248 | $5,80911 claims |
| Hikma Pharmaceuticals USAEpinephrine | $72 | $3,66720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in San Jose
- Alan GoldsobelSan Jose$66K
- Robert TorranoSan Jose$57K
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.